Product Information
ACITRETIN 17.5 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $4.5184 per EA under NDC 00093113856. Its NADAC has been published 155 times since Feb 18, 2015.
FDA first approved this application on Apr 4, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
17.5 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093113856
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACITRETINApproval Type
Generic (ANDA)
FDA Application
ANDA202897FDA Approved
4/4/2013
TE Code
AB
On Market Since
7/19/2013
Pharmacological Classes
Price Statistics
The NADAC for ACITRETIN 17.5 MG CAPSULE has been published 155 times since Feb 18, 2015, and over the history we have for it it has declined 81.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.5184 per EA |
|---|---|
| All-time high | $24.1687 (Mar 16, 2016) |
| All-time low | $4.5184 (Sep 23, 2026) |
| 52-week high | $7.9486 |
| 52-week low | $4.5184 |
| Median price | $10.3001 |
| Average price | $13.6118 |
| Largest weekly change | +55.6% (Jan 21, 2026) |
| Weeks tracked | 155 |
| Tracking since | Feb 18, 2015 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acitretin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACITRETIN 17.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ACITRETIN 17.5 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $4.5184 per EA (NDC 00093113856), effective Sep 30, 2026.
How has the price of ACITRETIN 17.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ACITRETIN 17.5 MG CAPSULE has declined 81.3%. It has been tracked across 155 weekly CMS publications since Feb 18, 2015.
What are the highest and lowest recorded NADAC prices for ACITRETIN 17.5 MG CAPSULE?
Since Feb 18, 2015, the NADAC for ACITRETIN 17.5 MG CAPSULE has ranged from a low of $4.5184 (Sep 23, 2026) to a high of $24.1687 (Mar 16, 2016), with a median of $10.3001 per EA.
Are there cheaper alternatives to ACITRETIN 17.5 MG CAPSULE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ACITRETIN 17.5 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures ACITRETIN 17.5 MG CAPSULE?
ACITRETIN 17.5 MG CAPSULE (NDC 00093113856) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.